A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts.
Journal Information
Full Title: CPT Pharmacometrics Syst Pharmacol
Abbreviation: CPT Pharmacometrics Syst Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST STATEMENT J.K., L.B., S.H., M.J., B.C., and S.U. were employed by AstraZeneca and may own stock. M.E. was on the advisory board for AMRA Medical AB, his department received research funds from AstraZeneca and lecture fees from Mediplast. All other authors declared no competing interests for this work. As an Editor‐in‐Training for CPT: Pharmacometrics & Systems Pharmacology, Jane Knöchel was not involved in the review or decision process for this paper."
Funding Disclosure
Evidence found in paper:
"FUNDING INFORMATION No funding was received for this work."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025